|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
on1222221548 |
| 003 |
OCoLC |
| 005 |
20240623213015.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
200915r20202014nyua fob 001 0 eng |
| 040 |
|
|
|a AU@
|b eng
|e rda
|e pn
|c AU@
|d OCLCO
|d OCLCF
|d ESU
|d STBDS
|d QGK
|d YDXIT
|d K6U
|d OCLCQ
|d OCLCO
|d OCLCQ
|d SFB
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|a 9780197563335
|q (electronic book)
|
| 020 |
|
|
|a 0197563333
|q (electronic book)
|
| 035 |
|
|
|a (OCoLC)1222221548
|
| 050 |
|
4 |
|a RM301.27
|b .T36 2020
|
| 049 |
|
|
|a HCDD
|
| 100 |
1 |
|
|a Tansey, Michael,
|e author.
|
| 245 |
1 |
0 |
|a Intelligent drug development :
|b trials and errors in clinical research /
|c Michael Tansey.
|
| 264 |
|
1 |
|a New York, NY :
|b Oxford University Press,
|c 2020.
|
| 264 |
|
4 |
|c ©2014
|
| 300 |
|
|
|a 1 online resource (240 pages) :
|b illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 336 |
|
|
|a still image
|b sti
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Previously issued in print: 2014.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 520 |
8 |
|
|a Clinical research is heavily regulated and involves coordination of numerous pharmaceutical-related disciplines. Each individual trial involves contractual, regulatory, and ethics approval at each site and in each country. Clinical trials have become so complex and government requirements so stringent that researchers often approach trials too cautiously, convinced that the process is bound to be insurmountably complicated and riddled with roadblocks. A step back is needed, anobjective examination of the drug development process as a whole, and recommendations made for streamlining the process at all stages. With this book, Tansey systematically addresses the key elements that affect the quality, timeliness, and cost-effectiveness of the drug-development process, and identifies steps that can be adjusted and made more efficient.
|
| 521 |
|
|
|a Specialized.
|
| 588 |
0 |
|
|a Publisher information
|
| 505 |
0 |
|
|a Cover; Intelligent Drug Development; Copyright; CONTENTS; Acknowledgments; Intelligent Drug Development; PART ONESetting the Scene; Introduction; Chapter 1 Aiming for Excellence; PART twoPlanning: From Chaos to Cosmos; Chapter 2 The Target Product Profile and Its Uses; Chapter 3 Planning the Individual Clinical Trial; PART ThreeThe Practicable Protocol; Chapter 4 Distilling the Essence of the Protocol: The Protocol Synopsis; Chapter 5 Redistillation: Eliminating Impurities by Carrying out Protocol Feasibility; Chapter 6 The Optimal Blend: The Approved Synopsis and the Final Protocol
|
| 505 |
8 |
|
|a PART FOURThe Sponsor, The Physician, and The Patient: The Eternal Clinical Trial TriangleChapter 7 Of Chickens and Eggs: The Sponsor's Dilemma; Chapter 8 Clinician or Clinical Trialist: The Physician's Dilemma; Chapter 9 What about the Customer? The Patient's Dilemma; PART FIVEAnd Another Thing ... ; Chapter 10 About Time: Making Meetings Matter; Chapter 11 The Brain-Scrambling, Fit-Inducing, Mind-Numbing Technicolor Laser Show; References; Index
|
| 650 |
|
0 |
|a Drug approval.
|
| 650 |
|
0 |
|a Clinical trials.
|
| 650 |
|
0 |
|a Drug development.
|
| 650 |
|
0 |
|a Medical protocols.
|
| 650 |
|
7 |
|a Clinical trials
|2 fast
|
| 650 |
|
7 |
|a Drug approval
|2 fast
|
| 650 |
|
7 |
|a Drug development
|2 fast
|
| 650 |
|
7 |
|a Medical protocols
|2 fast
|
| 776 |
0 |
8 |
|i Print version
|z 9780199974580
|
| 856 |
4 |
0 |
|u https://holycross.idm.oclc.org/login?auth=cas&url=https://academic.oup.com/book/40663
|y Click for online access
|
| 903 |
|
|
|a OUP-SOEBA
|
| 994 |
|
|
|a 92
|b HCD
|